2. Patients with established diagnosis of HFpEF: (1. Signs and Symptoms of Heart Failure. 2. Preserved Ejection Fraction (EF): EF greater than or equal to 50% is generally considered preserved. 3.Echo-cardiography: Evidence of left ventricular hypertrophy (LVH) or Evidence of diastolic dysfunction, such as impaired relaxation or increased stiffness of the left ventricle. 4.Elevated Natriuretic Peptides: serum N-terminal pro-B type natriuretic peptide (NT-proBNP) ≥400 pg/mL or brain natriuretic peptide ≥100 pg/mL can support the diagnosis of HFpEF in the presence of symptoms and other findings).
3. BMI \>27Kg/m2.
4. Adequate follow-up: Participants must be willing and able to comply with the study protocol and follow-up requirements.
You may not be if
1\. Age \<18 years. 2. Type 1 diabetes: Exclude individuals with type 1 diabetes, as dapagliflozin is primarily used for type 2 diabetes management.
3\. Significant renal impairment: Exclude participants with severe renal impairment or end-stage renal disease.
4\. Severe hepatic impairment: Exclude participants with severe hepatic dysfunction.
5\. Pregnancy or breastfeeding: Exclude pregnant or lactating individuals. 6. Patients who underwent Bariateric surgery. 7. BMI\<27Kg/m2. 8. Other serious medical conditions: Exclude participants with serious medical conditions that could interfere with the study or confound the results (e.g., cancer, severe infections).
9\. Inability to comply: Exclude participants who are unable or unwilling to comply with the study procedures and requirements.